

Anne Luise Haulund Vollesen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5371884/publications.pdf>

Version: 2024-02-01

231
papers

11,941
citations

30070

54
h-index

34986

98
g-index

236
all docs

236
docs citations

236
times ranked

4427
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Cerebral Perfusion, Oxygen Consumption, and Lactate Production in Response to Hypoxic Exposure. <i>Cerebral Cortex</i> , 2022, 32, 1295-1306.	2.9	8
2	PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. <i>Cephalalgia</i> , 2022, 42, 687-695.	3.9	8
3	Arterial responses to infusion of Glucagon-like Peptide-1 in humans: A randomized trial study. <i>Peptides</i> , 2022, 150, 170736.	2.4	0
4	Migraine and light: A narrative review. <i>Headache</i> , 2022, 62, 4-10.	3.9	13
5	Migraine. <i>Nature Reviews Disease Primers</i> , 2022, 8, 2.	30.5	154
6	Brain barriers and their potential role in migraine pathophysiology. <i>Journal of Headache and Pain</i> , 2022, 23, 16.	6.0	17
7	Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura. <i>JAMA Neurology</i> , 2022, 79, 159.	9.0	19
8	Prevalence of neck pain in migraine: A systematic review and meta-analysis. <i>Cephalalgia</i> , 2022, 42, 663-673.	3.9	36
9	Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies. <i>Cephalalgia</i> , 2022, 42, 781-792.	3.9	4
10	Effect of K ^{ATP} channel blocker glibenclamide on PACAP38-induced headache and hemodynamic. <i>Cephalalgia</i> , 2022, 42, 846-858.	3.9	13
11	Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies. <i>Journal of Headache and Pain</i> , 2022, 23, 43.	6.0	14
12	Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review. <i>Headache</i> , 2022, 62, 453-472.	3.9	9
13	Barriers and gaps in headache education: a national cross-sectional survey of neurology residents in Denmark. <i>BMC Medical Education</i> , 2022, 22, 233.	2.4	11
14	Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study. <i>Frontiers in Neurology</i> , 2022, 13, 871176.	2.4	6
15	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMIS [®] for research in migraine prevention. <i>Headache</i> , 2022, 62, 690-699.	3.9	6
16	Psychiatric Sequelae Following Whiplash Injury: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2022, 13, 814079.	2.6	3
17	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition. <i>Cephalalgia</i> , 2022, 42, 1099-1115.	3.9	5
18	Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. <i>Headache</i> , 2022, 62, 624-633.	3.9	4

#	ARTICLE	IF	CITATIONS
19	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. Journal of Headache and Pain, 2022, 23, .	6.0	143
20	One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey. Journal of Headache and Pain, 2022, 23, .	6.0	7
21	Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 604-616.	4.3	18
22	Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1328-1337.	4.3	14
23	Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers. Cephalalgia, 2021, 41, 99-111.	3.9	14
24	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia, 2021, 41, 6-16.	3.9	25
25	A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia, 2021, 41, 33-44.	3.9	65
26	Hypersensitivity to calcitonin gene-related peptide in chronic migraine. Cephalalgia, 2021, 41, 701-710.	3.9	20
27	Intradural artery dilation during experimentally induced migraine attacks. Pain, 2021, 162, 176-183.	4.2	12
28	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia, 2021, 41, 279-293.	3.9	24
29	Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. European Journal of Neurology, 2021, 28, 1716-1725.	3.3	112
30	Human Models. Headache, 2021, , 55-68.	0.4	4
31	Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. Cephalalgia, 2021, 41, 731-748.	3.9	19
32	Subtype-Specific Off-Label Treatment of Rosacea. Case Reports in Dermatology, 2021, 13, 121-128.	0.8	4
33	Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia, 2021, 41, 294-304.	3.9	34
34	Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain, 2021, 162, 2512-2520.	4.2	35
35	Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain, 2021, 144, 2322-2332.	7.6	48
36	Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers. Pharmacology Research and Perspectives, 2021, 9, e00741.	2.4	14

#	ARTICLE	IF	CITATIONS
37	Migraine: epidemiology and systems of care. Lancet, The, 2021, 397, 1485-1495.	13.7	310
38	Migraine: integrated approaches to clinical management and emerging treatments. Lancet, The, 2021, 397, 1505-1518.	13.7	139
39	Amylin Analog Pramlintide Induces Migraine-Like Attacks in Patients. Annals of Neurology, 2021, 89, 1157-1171.	5.3	58
40	Migraine: disease characterisation, biomarkers, and precision medicine. Lancet, The, 2021, 397, 1496-1504.	13.7	141
41	Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine. Neurology, 2021, 96, e2488-e2499.	1.1	29
42	Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020. Journal of Headache and Pain, 2021, 22, 22.	6.0	25
43	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. Cephalalgia, 2021, 41, 1135-1151.	3.9	19
44	Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study. Cephalalgia, 2021, 41, 1262-1267.	3.9	3
45	Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 2021, 17, 501-514.	10.1	194
46	Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine. Headache, 2021, 61, 916-926.	3.9	2
47	The Effect of KATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers. Frontiers in Physiology, 2021, 12, 652136.	2.8	14
48	Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment. Lancet Neurology, The, 2021, 20, 460-469.	10.2	56
49	Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. Journal of Headache and Pain, 2021, 22, 78.	6.0	32
50	The chronobiology of migraine: a systematic review. Journal of Headache and Pain, 2021, 22, 76.	6.0	14
51	Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. Journal of Headache and Pain, 2021, 22, 68.	6.0	23
52	Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. Journal of Investigative Dermatology, 2021, 141, 1687-1698.	0.7	11
53	Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. Journal of Headache and Pain, 2021, 22, 81.	6.0	11
54	Board Walk – August 2021. Cephalalgia, 2021, 41, 1033-1034.	3.9	0

#	ARTICLE	IF	CITATIONS
55	Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity. Headache, 2021, 61, 1180-1193.	3.9	8
56	Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches. JAMA Network Open, 2021, 4, e2118543.	5.9	38
57	Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study. Journal of Headache and Pain, 2021, 22, 98.	6.0	11
58	Timing and durability of response to erenumab in patients with chronic migraine. Headache, 2021, 61, 1255-1263.	3.9	9
59	Interictal pontine metabolism in migraine without aura patients: A 3 Tesla proton magnetic resonance spectroscopy study. Neurolmage: Clinical, 2021, 32, 102824.	2.7	7
60	PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Management, 2021, 11, 647-654.	1.5	12
61	Updates in the Diagnostic Approach of Headache. Current Pain and Headache Reports, 2021, 25, 80.	2.9	9
62	PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia, 2020, 40, 57-67.	3.9	57
63	Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1685-1694.	4.3	21
64	Ictal neck pain investigated in the interictal state – a search for the origin of pain. Cephalalgia, 2020, 40, 614-624.	3.9	23
65	Feasibility of Glutamate and GABA Detection in Pons and Thalamus at 3T and 7T by Proton Magnetic Resonance Spectroscopy. Frontiers in Neuroscience, 2020, 14, 559314.	2.8	17
66	Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study. Journal of Headache and Pain, 2020, 21, 134.	6.0	17
67	Latest Insights into the Pathophysiology of Migraine: the ATP-Sensitive Potassium Channels. Current Pain and Headache Reports, 2020, 24, 77.	2.9	18
68	Migraine with aura in women is not associated with structural thalamic abnormalities. Neurolmage: Clinical, 2020, 28, 102361.	2.7	10
69	<p>Reducing Episodic Cluster Headaches: Focus on Galcanezumab</p>. Journal of Pain Research, 2020, Volume 13, 1591-1599.	2.0	2
70	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia, 2020, 40, 1026-1044.	3.9	105
71	Googling migraine: A study of Google as an information resource of migraine management. Cephalalgia, 2020, 40, 1633-1644.	3.9	8
72	The migraine landscape on YouTube: A review of YouTube as a source of information on migraine. Cephalalgia, 2020, 40, 1363-1369.	3.9	10

#	ARTICLE	IF	CITATIONS
73	Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury. Cephalalgia, 2020, 40, 1276-1282.	3.9	17
74	Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache. Annals of Neurology, 2020, 88, 1220-1228.	5.3	35
75	The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. Cephalalgia, 2020, 40, 1474-1488.	3.9	14
76	Opening of BK _{Ca} channels alters cerebral hemodynamic and causes headache in healthy volunteers. Cephalalgia, 2020, 40, 1145-1154.	3.9	22
77	Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO). BMJ Open, 2020, 10, e039445.	1.9	5
78	Effect of K _{ATP} channel blocker glibenclamide on levromakalim-induced headache. Cephalalgia, 2020, 40, 1045-1054.	3.9	17
79	Intravascular Endothelin-1 does not trigger or increase susceptibility to Spreading Depolarizations. Journal of Headache and Pain, 2020, 21, 127.	6.0	2
80	Migraine. New England Journal of Medicine, 2020, 383, 1866-1876.	27.0	376
81	Neck pain and headache after whiplash injury: a systematic review and meta-analysis. Pain, 2020, 161, 880-888.	4.2	22
82	Post-Traumatic Stress Disorder After Traumatic Brain Injury—A Systematic Review and Meta-Analysis. Neurological Sciences, 2020, 41, 2737-2746.	1.9	29
83	The Stereotypical Image of a Person With Migraine According to Mass Media. Headache, 2020, 60, 1465-1471.	3.9	18
84	Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?. Headache, 2020, 60, 1056-1065.	3.9	58
85	Volume of the rectus capitis posterior minor muscle in migraine patients: a cross-sectional structural MRI study. Journal of Headache and Pain, 2020, 21, 57.	6.0	7
86	Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. Journal of Headache and Pain, 2020, 21, 62.	6.0	50
87	S100B and NSE in Cluster Headache – Evidence for Glial Cell Activation?. Headache, 2020, 60, 1569-1580.	3.9	4
88	Post-traumatic stress disorder attributed to traumatic brain injury in children – a systematic review. Brain Injury, 2020, 34, 857-863.	1.2	4
89	Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia, 2020, 40, 543-553.	3.9	74
90	Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. Journal of Headache and Pain, 2020, 21, 19.	6.0	12

#	ARTICLE	IF	CITATIONS
91	Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia, 2020, 40, 1212-1223.	3.9	30
92	Mechanistic Investigations Support Liver Safety of Ubrogapant. Toxicological Sciences, 2020, 177, 84-93.	3.1	13
93	Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura. Headache, 2020, 60, 655-664.	3.9	12
94	Targeting BKCa Channels in Migraine: Rationale and Perspectives. CNS Drugs, 2020, 34, 325-335.	5.9	18
95	Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia, 2020, 40, 241-254.	3.9	230
96	Persistent post-traumatic headache attributed to mild traumatic brain injury: Deep phenotyping and treatment patterns. Cephalalgia, 2020, 40, 554-564.	3.9	67
97	Reply: Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology. Brain, 2020, 143, e14-e14.	7.6	2
98	Risk Factors for the Development of Post-Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review. Headache, 2020, 60, 1066-1075.	3.9	20
99	Low frequency activation of the sphenopalatine ganglion does not induce migraine-like attacks in migraine patients. Cephalalgia, 2020, 40, 966-977.	3.9	3
100	Increased neck muscle stiffness in migraine patients with ictal neck pain: A shear wave elastography study. Cephalalgia, 2020, 40, 565-574.	3.9	18
101	Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura. Headache, 2020, 60, 724-734.	3.9	16
102	Current understanding of thalamic structure and function in migraine. Cephalalgia, 2019, 39, 1675-1682.	3.9	70
103	Migraine is associated with high brain 5-HT levels as indexed by 5-HT ₄ receptor binding. Cephalalgia, 2019, 39, 526-532.	3.9	12
104	Sildenafil and calcitonin gene-related peptide dilate intradural arteries: A 3T MR angiography study in healthy volunteers. Cephalalgia, 2019, 39, 264-273.	3.9	11
105	Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet, The, 2019, 394, 1030-1040.	13.7	269
106	Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain, 2019, 142, 2644-2654.	7.6	94
107	Board Walk “October 2019. Cephalalgia, 2019, 39, 1470-1471.	3.9	0
108	Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil. Cephalalgia, 2019, 39, 1776-1788.	3.9	18

#	ARTICLE	IF	CITATIONS
109	Extracranial activation of ATP-sensitive potassium channels induces vasodilation without nociceptive effects. <i>Cephalalgia</i> , 2019, 39, 1789-1797.	3.9	18
110	Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. <i>Cephalalgia</i> , 2019, 39, 1798-1808.	3.9	50
111	Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-blind Placebo-controlled Phase 3 Clinical Studies. <i>Headache</i> , 2019, 59, 1788-1801.	3.9	31
112	Levcromakalim, an Adenosine Triphosphate-sensitive Potassium Channel Opener, Dilates Extracerebral but not Cerebral Arteries. <i>Headache</i> , 2019, 59, 1468-1480.	3.9	36
113	Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. <i>Journal of Headache and Pain</i> , 2019, 20, 98.	6.0	64
114	Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study. <i>Peptides</i> , 2019, 121, 170134.	2.4	18
115	Calcitonin gene-related peptide "beyond migraine prophylaxis. <i>Nature Reviews Neurology</i> , 2019, 15, 562-564.	10.1	2
116	Post-traumatic headache: epidemiology and pathophysiological insights. <i>Nature Reviews Neurology</i> , 2019, 15, 607-617.	10.1	131
117	Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT _{1B} Receptor Binding. <i>JAMA Neurology</i> , 2019, 76, 834.	9.0	27
118	Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). <i>Journal of Headache and Pain</i> , 2019, 20, 60.	6.0	24
119	Migraine and the trigeminovascular system "40 years and counting. <i>Lancet Neurology</i> , The, 2019, 18, 795-804.	10.2	294
120	Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. <i>Cephalalgia</i> , 2019, 39, 1455-1464.	3.9	79
121	Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. <i>Cephalalgia</i> , 2019, 39, 1407-1420.	3.9	22
122	Ultra-high field MR angiography in human migraine models: a 3.0T/7.0T comparison study. <i>Journal of Headache and Pain</i> , 2019, 20, 48.	6.0	5
123	The changing faces of migraine. <i>Journal of Headache and Pain</i> , 2019, 20, 52.	6.0	1
124	Erenumab in chronic migraine with medication overuse. <i>Neurology</i> , 2019, 92, e2309-e2320.	1.1	163
125	Therapeutic novelties in migraine: new drugs, new hope?. <i>Journal of Headache and Pain</i> , 2019, 20, 37.	6.0	91
126	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2019, 39, 1058-1066.	3.9	4

#	ARTICLE	IF	CITATIONS
127	Calcitonin gene-related peptide and disease activity in cluster headache. Cephalalgia, 2019, 39, 575-584.	3.9	44
128	Neurovascular origin of primary headaches. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 571-572.	4.3	1
129	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 2019, 39, 687-710.	3.9	154
130	The vascular effect of glibenclamide: A systematic review. Cephalalgia Reports, 2019, 2, 251581631988493.	0.7	6
131	Effect of the H ₁ -antihistamine clemastine on PACAP38 induced migraine. Cephalalgia, 2019, 39, 597-607.	3.9	19
132	Meningeal contribution to migraine pain: a magnetic resonance angiography study. Brain, 2019, 142, 93-102.	7.6	74
133	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. Journal of Headache and Pain, 2019, 20, 6.	6.0	260
134	High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. Peptides, 2019, 112, 43-47.	2.4	6
135	Cortical abnormalities in episodic migraine: A multi-center 3T MRI study. Cephalalgia, 2019, 39, 665-673.	3.9	60
136	The most important advances in headache research in 2018. Lancet Neurology, The, 2019, 18, 5-6.	10.2	9
137	Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 680-689.	4.3	24
138	CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia, 2019, 39, 374-389.	3.9	58
139	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	3.9	245
140	ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia, 2018, 38, 1026-1037.	3.9	416
141	Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. Neurotherapeutics, 2018, 15, 371-376.	4.4	40
142	High brain serotonin levels in migraine between attacks: A 5-HT ₄ receptor binding PET study. Neurolmage: Clinical, 2018, 18, 97-102.	2.7	26
143	Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. Journal of Headache and Pain, 2018, 19, 11.	6.0	11
144	Migraine with visual aura associated with thicker visual cortex. Brain, 2018, 141, 776-785.	7.6	52

#	ARTICLE	IF	CITATIONS
145	The Role of Endothelin in the Pathophysiology of Migraine—a Systematic Review. <i>Current Pain and Headache Reports</i> , 2018, 22, 27.	2.9	32
146	Carbon monoxide inhalation induces headache but no migraine in patients with migraine without aura. <i>Cephalalgia</i> , 2018, 38, 1940-1949.	3.9	5
147	CGRP in human models of primary headaches. <i>Cephalalgia</i> , 2018, 38, 353-360.	3.9	26
148	Carbon monoxide inhalation induces headache in a human headache model. <i>Cephalalgia</i> , 2018, 38, 697-706.	3.9	9
149	Low 5-HT _{1B} receptor binding in the migraine brain: A PET study. <i>Cephalalgia</i> , 2018, 38, 519-527.	3.9	26
150	Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. <i>Cephalalgia</i> , 2018, 38, 892-903.	3.9	15
151	Cranial parasympathetic activation induces autonomic symptoms but no cluster headache attacks. <i>Cephalalgia</i> , 2018, 38, 1418-1428.	3.9	32
152	Altered thalamic connectivity during spontaneous attacks of migraine without aura: A resting-state fMRI study. <i>Cephalalgia</i> , 2018, 38, 1237-1244.	3.9	71
153	The relationship between migraine and rosacea: Systematic review and meta-analysis. <i>Cephalalgia</i> , 2018, 38, 1387-1398.	3.9	24
154	Vasomotor reactions in the face and head of patients with migraine. <i>Cephalalgia Reports</i> , 2018, 1, 251581631879054.	0.7	2
155	Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. <i>Journal of Headache and Pain</i> , 2018, 19, 105.	6.0	43
156	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2018, 19, 91.	6.0	97
157	Migraine and cluster headache – the common link. <i>Journal of Headache and Pain</i> , 2018, 19, 89.	6.0	44
158	Early onset of efficacy with erenumab in patients with episodic and chronic migraine. <i>Journal of Headache and Pain</i> , 2018, 19, 92.	6.0	78
159	Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0T. <i>Journal of Headache and Pain</i> , 2018, 19, 44.	6.0	14
160	Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks. <i>JAMA Neurology</i> , 2018, 75, 1187.	9.0	106
161	Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> , 2018, 38, 1611-1621.	3.9	104
162	Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?. <i>Journal of Headache and Pain</i> , 2018, 19, 33.	6.0	5

#	ARTICLE	IF	CITATIONS
163	CGRP in Human Models of Migraine. Handbook of Experimental Pharmacology, 2018, 255, 109-120.	1.8	34
164	Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura. Cephalalgia, 2017, 37, 74-88.	3.9	23
165	Challenges in developing drugs for primary headaches. Progress in Neurobiology, 2017, 152, 70-88.	5.7	25
166	PACAP38 dose-response pilot study in migraine patients. Cephalalgia, 2017, 37, 391-395.	3.9	17
167	Hypoxic mechanisms in primary headaches. Cephalalgia, 2017, 37, 372-384.	3.9	18
168	Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 114-124.	3.9	25
169	Serotonergic mechanisms in the migraine brain – a systematic review. Cephalalgia, 2017, 37, 251-264.	3.9	68
170	Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 125-135.	3.9	31
171	Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia, 2017, 37, 136-147.	3.9	46
172	Increased intrinsic brain connectivity between pons and somatosensory cortex during attacks of migraine with aura. Human Brain Mapping, 2017, 38, 2635-2642.	3.6	59
173	PACAP38: Emerging Drug Target in Migraine and Cluster Headache. Headache, 2017, 57, 56-63.	3.9	19
174	Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain, 2017, 140, 1633-1642.	7.6	105
175	Measurement of Blood Flow Velocity in the Middle Cerebral Artery During Spontaneous Migraine Attacks: A Systematic Review. Headache, 2017, 57, 852-861.	3.9	21
176	Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 425-434.	10.2	589
177	Lifelong contribution to headache science: A tribute to Professor Jes Olesen. Cephalalgia, 2017, 37, 7-7.	3.9	0
178	Calcitonin gene-related peptide and pain: a systematic review. Journal of Headache and Pain, 2017, 18, 34.	6.0	161
179	Triptans and CGRP blockade – impact on the cranial vasculature. Journal of Headache and Pain, 2017, 18, 103.	6.0	50
180	Human models of migraine – short-term pain for long-term gain. Nature Reviews Neurology, 2017, 13, 713-724.	10.1	165

#	ARTICLE	IF	CITATIONS
181	Erenumab (AMG 334) in episodic migraine. <i>Neurology</i> , 2017, 89, 1237-1243.	1.1	120
182	A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.63-e1.	1.9	9
183	Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses. <i>Annals of Neurology</i> , 2017, 82, 925-939.	5.3	41
184	Endovascular thrombectomy and post-procedural headache. <i>Journal of Headache and Pain</i> , 2017, 18, 10.	6.0	6
185	Prevalence and risk of migraine in patients with rosacea: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 454-458.	1.2	36
186	The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine. <i>Journal of Headache and Pain</i> , 2017, 18, 90.	6.0	42
187	PACAP38 in human models of primary headaches. <i>Journal of Headache and Pain</i> , 2017, 18, 110.	6.0	24
188	Sensory migraine aura is not associated with structural grey matter abnormalities. <i>NeuroImage: Clinical</i> , 2016, 11, 322-327.	2.7	42
189	Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. <i>Brain</i> , 2016, 139, 2015-2023.	7.6	74
190	Post procedure headache in patients treated for neurovascular arteriovenous malformations and aneurysms using endovascular therapy. <i>Journal of Headache and Pain</i> , 2016, 17, 73.	6.0	12
191	Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. <i>Pain</i> , 2016, 157, 2773-2781.	4.2	90
192	Migraine induced by hypoxia: an MRI spectroscopy and angiography study. <i>Brain</i> , 2016, 139, 723-737.	7.6	97
193	Change in brain network connectivity during PACAP38-induced migraine attacks. <i>Neurology</i> , 2016, 86, 180-187.	1.1	86
194	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 382-390.	10.2	312
195	Ultrasound tagged near infrared spectroscopy does not detect hyperventilation-induced reduction in cerebral blood flow. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 82-87.	1.2	5
196	Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteers. <i>Cephalalgia</i> , 2016, 36, 172-178.	3.9	14
197	Calcitonin Gene-Related Peptide Modulates Heat Nociception in the Human Brain - An fMRI Study in Healthy Volunteers. <i>PLoS ONE</i> , 2016, 11, e0150334.	2.5	29
198	Effect of motion artifacts and their correction on near-infrared spectroscopy oscillation data: a study in healthy subjects and stroke patients. <i>Journal of Biomedical Optics</i> , 2015, 20, 056011.	2.6	15

#	ARTICLE	IF	CITATIONS
199	Evidence of a Christmas spirit network in the brain: functional MRI study. <i>BMJ, The</i> , 2015, 351, h6266.	6.0	7
200	Structural gray matter abnormalities in migraine relate to headache lateralization, but not aura. <i>Cephalalgia</i> , 2015, 35, 3-9.	3.9	30
201	The temporal evolution of a facial pain syndrome associated with neurovascular contact: a case report. <i>Journal of Headache and Pain</i> , 2015, 16, 12.	6.0	1
202	Can nitric oxide induce migraine in normal individuals?. <i>Cephalalgia</i> , 2015, 35, 1125-1129.	3.9	11
203	Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 Tesla. <i>Journal of Neuroscience</i> , 2015, 35, 13800-13806.	3.6	62
204	Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. <i>Peptides</i> , 2015, 74, 33-42.	2.4	11
205	Cerebral Asymmetry of fMRI-BOLD Responses to Visual Stimulation. <i>PLoS ONE</i> , 2015, 10, e0126477.	2.5	23
206	Research update for articles published in <i>EJCI</i> in 2012. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1010-1023.	3.4	1
207	Carbon monoxide may be an important molecule in migraine and other headaches. <i>Cephalalgia</i> , 2014, 34, 1169-1180.	3.9	19
208	Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta. <i>Cephalalgia</i> , 2014, 34, 712-716.	3.9	15
209	Measurement precision and biological variation of cranial arteries using automated analysis of 3 T magnetic resonance angiography. <i>Journal of Headache and Pain</i> , 2014, 15, 25.	6.0	19
210	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology, The</i> , 2014, 13, 1100-1107.	10.2	333
211	Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. <i>Brain</i> , 2014, 137, 779-794.	7.6	196
212	Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. <i>Brain</i> , 2014, 137, 2951-2959.	7.6	88
213	Natriuretic peptides and cerebral hemodynamics. <i>Regulatory Peptides</i> , 2014, 192-193, 15-23.	1.9	9
214	Calcitonin gene-related peptide and migraine with aura: A systematic review. <i>Cephalalgia</i> , 2014, 34, 695-707.	3.9	26
215	Migraine without aura is not associated with incomplete circle of Willis: a case-control study using high-resolution magnetic resonance angiography. <i>Journal of Headache and Pain</i> , 2014, 15, 27.	6.0	6
216	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan. <i>Scandinavian Journal of Pain</i> , 2013, 4, 211-216.	1.3	6

#	ARTICLE	IF	CITATIONS
217	Intracranial and extracranial arteries in migraine – Authors' reply. <i>Lancet Neurology</i> , The, 2013, 12, 848-849.	10.2	1
218	Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience. <i>Cephalalgia</i> , 2013, 33, 540-553.	3.9	83
219	Provocation of migraine with aura using natural trigger factors. <i>Neurology</i> , 2013, 80, 428-431.	1.1	107
220	Altered Low Frequency Oscillations of Cortical Vessels in Patients with Cerebrovascular Occlusive Disease – A NIRS Study. <i>Frontiers in Neurology</i> , 2013, 4, 204.	2.4	11
221	Vascular changes have a primary role in migraine. <i>Cephalalgia</i> , 2012, 32, 428-430.	3.9	19
222	Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. <i>Cephalalgia</i> , 2012, 32, 140-149.	3.9	111
223	Migraine neurobiology and treatment. <i>Scandinavian Journal of Pain</i> , 2012, 3, 176-176.	1.3	0
224	Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. <i>Cephalalgia</i> , 2011, 31, 683-690.	3.9	29
225	Trigger factors for familial hemiplegic migraine. <i>Cephalalgia</i> , 2011, 31, 1274-1281.	3.9	36
226	Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. <i>Cephalalgia</i> , 2010, 30, 1179-1186.	3.9	365
227	Pharmacological migraine provocation: a human model of migraine. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 773-779.	1.8	2
228	PACAP38 induces migraine-like attacks in patients with migraine without aura. <i>Brain</i> , 2009, 132, 16-25.	7.6	360
229	Pathophysiology of Tension-Type Headache: Potential Drug Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2007, 6, 238-239.	1.4	9
230	No release of interstitial glutamate in experimental human model of muscle pain. <i>European Journal of Pain</i> , 2005, 9, 337-337.	2.8	13
231	Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 395-399.	1.8	29